Laparoscopic Transversus Abdominis Plane (TAP) Block to Reduce Post-operative Opioids

Withdrawn before enrolling · Phase 2/Phase 3

Conditions studied: Opioid Use

In brief

This study evaluates laparoscopic-guided TAP block for reducing opioid use after minimally invasive foregut and bariatric surgeries, comparing Bupivacaine HCL with Exparel®. Secondary outcomes include pain scores, length of stay, and PONV medication use.

Key facts

Study ID

NCT04655339

Run by

Baylor Research Institute

People needed

0

Starts

2020-01-24

Expected to finish

2021-09-03

Last updated by the study team

2026-02-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• gastric bypass \& sleeve gastrectomy, duodenal switch and minimally invasive elective anti-reflux foregut surgeries such as - hiatal hernia repair, fundoplication and Heller myotomy.

You may not qualify if…

• Subjects who are known to be
• Allergic to Bupivacaine
• Chronic opioid users Page 4
• Had/have neurological conditions
• Have a diagnosis of chronic pain syndrome which requires them to consume regular analgesics > 3-months
• American Society of Anesthesiologists (ASA) Class IV \& V patients with severe systemic disease that is a constant threat to life.
• Patients with abdominal drain use
• Patients with significant cardiovascular, liver or renal disease
• Presence of contraindications for bariatric or foregut surgery.
• Patients presenting postoperative complications will be excluded from final analysis \& final data set
• History of bariatric or foregut surgery
• Patients who are pregnant
• Patients who are under the age of 18

Where it is running

• Baylor University Medical Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.